{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:32:22Z","timestamp":1790800342827,"version":"4.1.0"},"reference-count":176,"publisher":"Bentham Science Publishers Ltd.","issue":"32","funder":[{"DOI":"10.13039\/501100007161","name":"Secretaria de Investigaci\u00f3n y Posgrado del Instituto Polit\u00e9cnico Nacional","doi-asserted-by":"publisher","award":["SIP-20200491"],"award-info":[{"award-number":["SIP-20200491"]}],"id":[{"id":"10.13039\/501100007161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,9,25]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Parasitic diseases, caused by helminths (ascariasis, hookworm, trichinosis, and schistosomiasis)\nand protozoa (chagas, leishmaniasis, and amebiasis), are considered a serious public\nhealth problem in developing countries. Additionally, there is a limited arsenal of anti-parasitic\ndrugs in the current pipeline and growing drug resistance. Therefore, there is a clear need for the\ndiscovery and development of new compounds that can compete and replace these drugs that have\nbeen controlling parasitic infections over the last decades. However, this approach is highly resource-\nintensive, expensive and time-consuming. Accordingly, a drug repositioning strategy of the\nexisting drugs or drug-like molecules with known pharmacokinetics and safety profiles is alternatively\nbeing used as a fast approach towards the identification of new treatments. The artemisinins,\nmefloquine, tribendimidine, oxantel pamoate and doxycycline for the treatment of helminths, and\nposaconazole and hydroxymethylnitrofurazone for the treatment of protozoa are promising candidates.\nTherefore, traditional antiprotozoal drugs, which were developed in some cases decades ago,\nare a valid solution. Herein, we review the current status of traditional anti-helminthic and antiprotozoal\ndrugs in terms of drug targets, mode of action, doses, adverse effects, and parasite resistance\nto define their suitability for repurposing strategies. Current antiparasitic drugs are not only\nstill viable for the treatment of helminth and protozoan infections but are also important candidates\nfor new pharmacological treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666190628163633","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T12:11:52Z","timestamp":1562069512000},"page":"5403-5428","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Old Antiprotozoal Drugs: Are They Still Viable Options for Parasitic Infections or New Options for Other Diseases?"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-1835","authenticated-orcid":true,"given":"Sandra","family":"Cortez-Maya","sequence":"first","affiliation":[{"name":"Instituto de Quimica, Universidad Nacional Autonoma de Mexico, Cd. Universitaria, Circuito Exterior, Coyoacan, 04510 Ciudad de Mexico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7541-1267","authenticated-orcid":true,"given":"Antonio","family":"Moreno-Herrera","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-531X","authenticated-orcid":true,"given":"Isidro","family":"Palos","sequence":"additional","affiliation":[{"name":"Unidad AcadEmica Multidisciplinaria Reynosa-Rodhe, Universidad AutOnoma de Tamaulipas, 88710 Reynosa, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-4167","authenticated-orcid":true,"given":"Gildardo","family":"Rivera","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnologia Farmaceutica, Centro de Biotecnologia Genomica, Instituto Politecnico Nacional, 88710 Reynosa, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"WHO Health topic: neglected tropical diseases  Available at: (Accessed Date: 17th May, 2017)","journal-title":"WHO Health topic: neglected tropical diseases  Available at:"},{"key":"ref=2","year":"2012","unstructured":"World Health Organization Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases a Roadmap for Implementation 2012","journal-title":"World Health Organization Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases a Roadmap for Implementation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJM199605023341808","volume":"334","author":"Liu L.X.","year":"1996","unstructured":"Liu L.X.; Weller P.F.; Peter F.; Weller M.D.; Antiparasitic drugs. N Engl J Med 1996,334(18),1178-1184","journal-title":"N Engl J Med"},{"key":"ref=4","year":"1995","unstructured":"WHO model prescribing information: drugs used in parasitic diseases World Health Organization 2nd  Edition, 1995","journal-title":"WHO model prescribing information: drugs used in parasitic diseases World Health Organization 2nd  Edition,"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1056\/NEJMoa066536","volume":"356","author":"Sundar S.","year":"2007","unstructured":"Sundar S.; Jha T.K.; Thakur C.P.; Sinha P.K.; Bhattacharya S.K.; Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007,356(25),2571-2581","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijpddr.2014.07.002","volume":"4","author":"Panic G.","year":"2014","unstructured":"Panic G.; Duthaler U.; Speich B.; Keiser J.; Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist 2014,4(3),185-200","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ejmech.2018.06.040","volume":"155","author":"Scarim C.B.","year":"2018","unstructured":"Scarim C.B.; Jornada D.H.; Chelucci R.C.; de Almeida L.; Dos Santos J.L.; Chung M.C.; Current advances in drug discovery for Chagas disease. Eur J Med Chem 2018,155,824-838","journal-title":"Eur J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1021\/ja01468a052","volume":"83","author":"Breslow R.","year":"1961","unstructured":"Breslow R.; Bahary W.; Reinmuth W.; Antiparasitic drugs. Iv. 2-(4\u2032-Thiazolyl) Benzimidazole, a new anthelmintic. J Am Chem Soc 1961,83(7),1764-1765","journal-title":"J Am Chem Soc"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5216\/rpt.v46i2.47571","volume":"46","author":"Vinaud M.C.","year":"2017","unstructured":"Vinaud M.C.; de Souza R.; Mode of action of the main anti-parasitic drugs. Rev Patol Trop 2017,46(2),121-133","journal-title":"Rev Patol Trop"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0169-4758(90)90227-U","volume":"6","author":"Lacey E.","year":"1990","unstructured":"Lacey E.; Mode of action of benzimidazoles. Parasitol Today 1990,6(4),112-115","journal-title":"Parasitol Today"},{"key":"ref=11","first-page":"505","volume":"31","author":"Delatour P.","year":"1976","unstructured":"Delatour P.; Richard Y.; The embryotoxic and antimitotic properties of a series of benzimidazoles Therapie 1976,31(4),505-515","journal-title":"Therapie"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/0020-7519(88)90175-0","volume":"18","author":"Lacey E.","year":"1988","unstructured":"Lacey E.; The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1988,18(7),885-936","journal-title":"Int J Parasitol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.14712\/18059694.2017.44","volume":"60","author":"\u010c\u00e1\u0148ov\u00e1 K.","year":"2017","unstructured":"\u010c\u00e1\u0148ov\u00e1 K.; Rozkydalov\u00e1 L.; Rudolf E.; Anthelmintic flubendazole and its potential use in anticancer therapy. Acta Med (Hradec Kralove) 2017,60(1),5-11","journal-title":"Acta Med (Hradec Kralove)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"Jordan M.A.","year":"2004","unstructured":"Jordan M.A.; Wilson L.; Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004,4(4),253-265","journal-title":"Nat Rev Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","volume":"12","author":"Pourgholami M.H.","year":"2006","unstructured":"Pourgholami M.H.; Yan Cai ; Z.; Lu, Y.; Wang, L.; Morris, D.L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006,12(6),1928-1935","journal-title":"Clin Cancer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0035-9203(82)90034-7","volume":"76","author":"Grove D.I.","year":"1982","unstructured":"Grove D.I.; Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982,76(1),114-118","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1517\/14656566.5.12.2615","volume":"5","author":"Igual-Adell R.","year":"2004","unstructured":"Igual-Adell R.; Oltra-Alcaraz C.; Soler-Company E.; S\u00e1nchez-S\u00e1nchez P.; Matogo-Oyana J.; Rodr\u00edguez-Calabuig D.; Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004,5(12),2615-2619","journal-title":"Expert Opin Pharmacother"},{"key":"ref=18","first-page":"519","volume":"Vol. 1","author":"James S.","year":"2015","unstructured":"James S.; McCarthy T.A.;  Principles and Practice of Infectious Diseases 2015,Vol. 1,519-527.e3","journal-title":"Principles and Practice of Infectious Diseases"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1016\/j.bmc.2015.03.085","volume":"23","author":"Zhang C.","year":"2015","unstructured":"Zhang C.; Zhong B.; Yang S.; Liangkun., Yu; S., Li, Z.; Li, S.; Su, B.; Meng, X. Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents. Bioorg Med Chem 2015,23(13),3774-3780","journal-title":"Bioorg Med Chem"},{"key":"ref=20","unstructured":"WHO model list of essential medicines. World Health Organization, 2015. Available at: (Accessed Date: 21st June, 2017)."},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4269\/ajtmh.1983.32.118","volume":"32","author":"Kan S.P.","year":"1983","unstructured":"Kan S.P.; Efficacy of single doses of mebendazole in the treatment of Trichuris trichiura infection. Am J Trop Med Hyg 1983,32(1),118-122","journal-title":"Am J Trop Med Hyg"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1017\/S0022149X17000426","volume":"92","author":"Mrus J.","year":"2018","unstructured":"Mrus J.; Baeten B.; Engelen M.; Silber S.A.; Efficacy of single-dose 500 mg mebendazole in soil-transmitted helminth infections: a review. J Helminthol 2018,92(3),269-278","journal-title":"J Helminthol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.7326\/0003-4819-91-4-582","volume":"91","author":"Keystone J.S.","year":"1979","unstructured":"Keystone J.S.; Murdoch J.K.; Mebendazole. Ann Intern Med 1979,91(4),582-586","journal-title":"Ann Intern Med"},{"key":"ref=24","unstructured":"Summary of product characteristics. Available at:  (Accessed Date: 21st June, 2017)."},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1128\/CMR.13.2.207","volume":"13","author":"Geerts S.","year":"2000","unstructured":"Geerts S.; Gryseels B.; Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 2000,13(2),207-222","journal-title":"Clin Microbiol Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fmicb.2017.00535","volume":"8","author":"Joffe L.S.","year":"2017","unstructured":"Joffe L.S.; Schneider R.; Lopes W.; Azevedo R.; Staats C.C.; Kmetzsch L.; Schrank A.; Del Poeta M.; Vainstein M.H.; Rodrigues M.L.; The anti-helminthic compound mebendazole has multiple antifungal effects against cryptococcus neoformans. Front Microbiol 2017,8(535),535","journal-title":"Front Microbiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2119\/molmed.2017.00011","volume":"23","author":"De Witt M.","year":"2017","unstructured":"De Witt M.; Gamble A.; Hanson D.; Markowitz D.; Powell C.; Al Dimassi S.; Atlas M.; Boockvar J.; Ruggieri R.; Symons M.; Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol Med 2017,23,50-56","journal-title":"Mol Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tiv.2017.06.007","volume":"43","author":"Celestino Pinto L.","year":"2017","unstructured":"Celestino Pinto L.; de F\u00e1tima Aquino Moreira-Nunes C.; Soares B.M.; Burbano R.M.R.; de Lemos J.A.R.; Montenegro R.C.; Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicol In Vitro 2017,43,87-91","journal-title":"Toxicol In Vitro"},{"key":"ref=29","first-page":"1201","volume":"1","author":"Sasaki J.","year":"2002","unstructured":"Sasaki J.; Ramesh R.; Chada S.; Gomyo Y.; Roth J.A.; Mukhopadhyay T.; The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002,1(13),1201-1209","journal-title":"Mol Cancer Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"Bai R.Y.","year":"2011","unstructured":"Bai R.Y.; Staedtke V.; Aprhys C.M.; Gallia G.L.; Riggins G.J.; Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncol 2011,13(9),974-982","journal-title":"Neuro-oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/0035-9203(83)90199-2","volume":"77","author":"Kan S.P.","year":"1983","unstructured":"Kan S.P.; The anthelmintic effects of flubendazole on Trichuris trichiura and Ascaris lumbricoides. Trans R Soc Trop Med Hyg 1983,77(5),668-670","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1345\/aph.1D325","volume":"38","author":"Bagheri H.","year":"2004","unstructured":"Bagheri H.; Simiand E.; Montastruc J.L.; Magnaval J.F.; Adverse drug reactions to anthelmintics. Ann Pharmacother 2004,38(3),383-388","journal-title":"Ann Pharmacother"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006436","volume":"13","author":"Geary T.G.","year":"2019","unstructured":"Geary T.G.; Mackenzie C.D.; Silber S.A.; Flubendazole as a macrofilaricide: history and background. PLoS Negl Trop Dis 2019,13(1)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/eri.11.30","volume":"9","author":"Mackenzie C.D.","year":"2011","unstructured":"Mackenzie C.D.; Geary T.G.; Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther 2011,9(5),497-501","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijpddr.2015.09.001","volume":"5","author":"Ceballos L.","year":"2015","unstructured":"Ceballos L.; Alvarez L.; Mackenzie C.; Geary T.; Lanusse C.; Pharmacokinetic comparison of different flubendazole formulations in pigs: a further contribution to its development as a macrofilaricide molecule. Int J Parasitol Drugs Drug Resist 2015,5(3),178-184","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8202","DOI":"10.1038\/srep08202","volume":"5","author":"Michaelis M.","year":"2015","unstructured":"Michaelis M.; Agha B.; Rothweiler F.; L\u00f6schmann N.; Voges Y.; Mittelbronn M.; Starzetz T.; Harter P.N.; Abhari B.A.; Fulda S.; Westermann F.; Riecken K.; Spek S.; Langer K.; Wiese M.; Dirks W.G.; Zehner R.; Cinatl J.; Wass M.N.; Cinatl J.; Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci Rep 2015,5(8202),8202","journal-title":"Sci Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.18632\/oncotarget.3436","volume":"6","author":"Hou Z.J.","year":"2015","unstructured":"Hou Z.J.; Luo X.; Zhang W.; Peng F.; Cui B.; Wu S.J.; Zheng F.M.; Xu J.; Xu L.Z.; Long Z.J.; Wang X.T.; Li G.H.; Wan X.Y.; Yang Y.L.; Liu Q.; Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget 2015,6(8),6326-6340","journal-title":"Oncotarget"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1039\/C5MB00466G","volume":"11","author":"Zhang L.","year":"2015","unstructured":"Zhang L.; Guo M.; Li J.; Zheng Y.; Zhang S.; Xie T.; Liu B.; Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer. Mol Biosyst 2015,11(11),2860-2866","journal-title":"Mol Biosyst"},{"key":"ref=39","first-page":"383","volume":"64","author":"Davis A.","year":"1986","unstructured":"Davis A.; Pawlowski Z.S.; Dixon H.; Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bull World Health Organ 1986,64(3),383-388","journal-title":"Bull World Health Organ"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actatropica.2009.11.001","volume":"114","author":"Brunetti E.","year":"2010","unstructured":"Brunetti E.; Kern P.; Vuitton D.A.; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010,114(1),1-16","journal-title":"Acta Trop"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3346\/jkms.2008.23.5.903","volume":"23","author":"Choi G.Y.","year":"2008","unstructured":"Choi G.Y.; Yang H.W.; Cho S.H.; Kang D.W.; Go H.; Lee W.C.; Lee Y.J.; Jung S.H.; Kim A.N.; Cha S.W.; Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci 2008,23(5),903-905","journal-title":"J Korean Med Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0035-9203(90)90324-8","volume":"84","author":"Meloni B.P.","year":"1990","unstructured":"Meloni B.P.; Thompson R.C.A.; Reynoldson J.A.; Seville P.; Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans R Soc Trop Med Hyg 1990,84(3),375-379","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.actatropica.2015.09.023","volume":"153","author":"Escobedo A.A.","year":"2016","unstructured":"Escobedo A.A.; Ballesteros J.; Gonz\u00e1lez-Fraile E.; Almirall P.; A meta-analysis of the efficacy of albendazole compared with tinidazole as treatments for Giardia infections in children. Acta Trop 2016,153,120-127","journal-title":"Acta Trop"},{"key":"ref=44","first-page":"288","volume":"29","author":"Cobo F.","year":"2016","unstructured":"Cobo F.; Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp Quimioter 2016,29(6),288-295","journal-title":"Rev Esp Quimioter"},{"key":"ref=45","first-page":"19","volume":"10","author":"Jayakody R.L.","year":"1993","unstructured":"Jayakody R.L.; de Silva C.S.S.; Weerasinghe W.M.T.; Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Trop Biomed 1993,10,19-24","journal-title":"Trop Biomed"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.7326\/0003-4819-145-1-200607040-00009","volume":"145","author":"Del Brutto O.H.","year":"2006","unstructured":"Del Brutto O.H.; Roos K.L.; Coffey C.S.; Garc\u00eda H.H.; Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006,145(1),43-51","journal-title":"Ann Intern Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1473-3099(14)70779-0","volume":"14","author":"Garcia H.H.","year":"2014","unstructured":"Garcia H.H.; Gonzales I.; Lescano A.G.; Bustos J.A.; Zimic M.; Escalante D.; Saavedra H.; Gavidia M.; Rodriguez L.; Najar E.; Umeres H.; Pretell E.J.; Cysticercosis working group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 2014,14(8),687-695","journal-title":"Lancet Infect Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1748-717X-6-160","volume":"6","author":"Patel K.","year":"2011","unstructured":"Patel K.; Doudican N.A.; Schiff P.B.; Orlow S.J.; Albendazole sensitizes cancer cells to ionizing radiation. Radiat Oncol 2011,6,160","journal-title":"Radiat Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0304-3835(01)00382-2","volume":"165","author":"Pourgholami M.H.","year":"2001","unstructured":"Pourgholami M.H.; Woon L.; Almajd R.; Akhter J.; Bowery P.; Morris D.L.; In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001,165(1),43-49","journal-title":"Cancer Lett"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00280-004-0927-6","volume":"55","author":"Pourgholami M.H.","year":"2005","unstructured":"Pourgholami M.H.; Akhter J.; Wang L.; Lu Y.; Morris D.L.; Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 2005,55(5),425-432","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3892\/etm.2016.3992","volume":"13","author":"Zhang X.","year":"2017","unstructured":"Zhang X.; Zhao J.; Gao X.; Pei D.; Gao C.; Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis. Exp Ther Med 2017,13(2),595-603","journal-title":"Exp Ther Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"71512","DOI":"10.18632\/oncotarget.17292","volume":"8","author":"Ghasemi F.","year":"2017","unstructured":"Ghasemi F.; Black M.; Vizeacoumar F.; Pinto N.; Ruicci K.M.; Le C.C.S.H.; Lowerison M.R.; Leong H.S.; Yoo J.; Fung K.; MacNeil D.; Palma D.A.; Winquist E.; Mymryk J.S.; Boutros P.C.; Datti A.; Barrett J.W.; Nichols A.C.; Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. Oncotarget 2017,8(42),71512-71519","journal-title":"Oncotarget"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/AAC.15.3.361","volume":"15","author":"Burg R.W.","year":"1979","unstructured":"Burg R.W.; Miller B.M.; Baker E.E.; Birnbaum J.; Currie S.A.; Hartman R.; Kong, Y.L.; Monaghan, R.L.; Olson, G.; Putter, I.; Tunac, J.B.; Wallick, H.; Stapley, E.O.; Oiwa, R.; Omura, S. A vermectins, new family of potent anthelmintic agents: Producing organism and fermentation. Antimicrob Agents Chemother 1979,15,361-367","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1021\/jm00184a014","volume":"23","author":"Chabala J.C.","year":"1980","unstructured":"Chabala J.C.; Mrozik H.; Tolman R.L.; Eskola P.; Lusi A.; Peterson L.H.; Woods M.F.; Fisher M.H.; Campbell W.C.; Egerton J.R.; Ostlind D.A.; Ivermectin, a new broad-spectrum antiparasitic agent. J Med Chem 1980,23(10),1134-1136","journal-title":"J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","volume":"33","author":"Laing R.","year":"2017","unstructured":"Laing R.; Gillan V.; Devaney E.; Ivermectin - old drug, new tricks? Trends Parasitol 2017,33(6),463-472","journal-title":"Trends Parasitol"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007745.pub3","volume":"1","author":"Henriquez-Camacho C.","year":"2016","unstructured":"Henriquez-Camacho C.; Gotuzzo E.; Echevarria J.; White A.C.; Terashima A.; Samalvides F.; P\u00e9rez-Molina J.A.; Plana M.N.; Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 2016,1(1)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=57","first-page":"384","volume":"80","author":"Winnen M.","year":"2002","unstructured":"Winnen M.; Plaisier A.P.; Alley E.S.; Nagelkerke N.J.; van Oortmarssen G.; Boatin B.A.; Habbema J.D.; Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 2002,80(5),384-391","journal-title":"Bull World Health Organ"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1179\/000349802125002374","volume":"96","author":"Molyneux D.H.","year":"2002","unstructured":"Molyneux D.H.; Zagaria N.; Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol 2002,96(Suppl. 2),S15-S40","journal-title":"Ann Trop Med Parasitol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.bmc.2008.12.003","volume":"17","author":"dos Santos A.R.","year":"2009","unstructured":"dos Santos A.R.; Falc\u00e3o C.A.; Muzitano M.F.; Kaiser C.R.; Rossi-Bergmann B.; F\u00e9r\u00e9zou J.P.; Ivermectin-derived leishmanicidal compounds. Bioorg Med Chem 2009,17(2),496-502","journal-title":"Bioorg Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clindermatol.2005.11.008","volume":"24","author":"Enk C.D.","year":"2006","unstructured":"Enk C.D.; Onchocerciasis--river blindness. Clin Dermatol 2006,24(3),176-180","journal-title":"Clin Dermatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1365-4632.2004.02253.x","volume":"44","author":"Dourmishev A.L.","year":"2005","unstructured":"Dourmishev A.L.; Dourmishev L.A.; Schwartz R.A.; Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005,44(12),981-988","journal-title":"Int J Dermatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0169-4758(85)90100-0","volume":"1","author":"Campbell W.C.","year":"1985","unstructured":"Campbell W.C.; Ivermectin: an update. Parasitol Today 1985,1(1),10-16","journal-title":"Parasitol Today"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","volume":"98","author":"Chandler R.E.","year":"2018","unstructured":"Chandler R.E.; Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg 2018,98(2),382-388","journal-title":"Am J Trop Med Hyg"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12936-017-1803-2","volume":"16","author":"Chaccour C.","year":"2017","unstructured":"Chaccour C.; Rabinovich N.R.; Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways. Malar J 2017,16(1),162","journal-title":"Malar J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/infdis\/jis184","volume":"205","author":"da Cruz F.P.","year":"2012","unstructured":"da Cruz F.P.; Martin C.; Buchholz K.; Lafuente-Monasterio M.J.; Rodrigues T.; S\u00f6nnichsen B.; Moreira R.; Gamo F.J.; Marti M.; Mota M.M.; Hannus M.; Prud\u00eancio M.; Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis 2012,205(8),1278-1286","journal-title":"J Infect Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0140-6736(94)91625-X","volume":"343","author":"Costa J.L.","year":"1994","unstructured":"Costa J.L.; Diazgranados J.A.; Ivermectin for spasticity in spinal-cord injury. Lancet 1994,343(8899),739","journal-title":"Lancet"},{"key":"ref=67","first-page":"317","volume":"8","author":"Juarez M.","year":"2018","unstructured":"Juarez M.; Schcolnik-Cabrera A.; Due\u00f1as-Gonzalez A.; The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res 2018,8(2),317-331","journal-title":"Am J Cancer Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1182\/blood-2010-01-262675","volume":"116","author":"Sharmeen S.","year":"2010","unstructured":"Sharmeen S.; Skrtic M.; Sukhai M.A.; Hurren R.; Gronda M.; Wang X.; Fonseca S.B.; Sun H.; Wood T.E.; Ward R.; Minden M.D.; Batey R.A.; Datti A.; Wrana J.; Kelley S.O.; Schimmer A.D.; The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood 2010,116(18),3593-3603","journal-title":"Blood"},{"key":"ref=69","first-page":"R1","volume":"82","author":"Mackenzie C.D.","year":"1985","unstructured":"Mackenzie C.D.; Kron M.A.; Diethylcarbamazine: a review of its action in onchocerciasis, lymphatic filariasis and inflammation. Trop Dis Bull 1985,82,R1-R36","journal-title":"Trop Dis Bull"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/civ882","volume":"62","author":"Thomsen E.K.","year":"2016","unstructured":"Thomsen E.K.; Sanuku N.; Baea M.; Satofan S.; Maki E.; Lombore B.; Schmidt M.S.; Siba P.M.; Weil G.J.; Kazura J.W.; Fleckenstein L.L.; King C.L.; Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 2016,62(3),334-341","journal-title":"Clin Infect Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0166-6851(91)90125-P","volume":"49","author":"Kanesa-thasan N.","year":"1991","unstructured":"Kanesa-thasan N.; Douglas J.G.; Kazura J.W.; Diethylcarbamazine inhibits endothelial and microfilarial prostanoid metabolism in vitro. Mol Biochem Parasitol 1991,49(1),11-19","journal-title":"Mol Biochem Parasitol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1017\/S0031182000075351","volume":"105","author":"Maizels R.M.","year":"1992","unstructured":"Maizels R.M.; Denham D.A.; Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitology 1992,105(Suppl.),S49-S60","journal-title":"Parasitology"},{"key":"ref=73","unstructured":"WHO model prescribing information: drugs used in parasitic diseases-second edition. World Health Organization, 1995. Available at:  (Accessed Date: 29th June, 2017)"},{"key":"ref=74","unstructured":"Essential medicines and health products information portal. WHO, 2017. Available at:   (Accessed Date: 21st June, 2017)"},{"key":"ref=75","unstructured":"Summary of product characteristics for notezine. Sanofi, (Accessed Date: 29th September, 2017)"},{"key":"ref=76","first-page":"682","volume":"16","author":"Vargas L.","year":"1957","unstructured":"Vargas L.; Tovar J.; Resistance of Onchocerca volvulus microfilariae to diethylcarbamazine. Bull World Health Organ 1957,16(3),682-683","journal-title":"Bull World Health Organ"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejphar.2014.03.046","volume":"734","author":"Peixoto C.A.","year":"2014","unstructured":"Peixoto C.A.; Silva B.S.; Anti-inflammatory effects of diethylcarbamazine: a review. Eur J Pharmacol 2014,734(34),35-41","journal-title":"Eur J Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.idc.2012.03.004","volume":"26","author":"Gryseels B.","year":"2012","unstructured":"Gryseels B.; Schistosomiasis. Infect Dis Clin North Am 2012,26(2),383-397","journal-title":"Infect Dis Clin North Am"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001917","volume":"6","author":"Coulibaly J.T.","year":"2012","unstructured":"Coulibaly J.T.; N\u2019gbesso Y.K.; Knopp S.; Keiser J.; N\u2019Goran E.K.; Utzinger J.; Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis 2012,6(12)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jac\/dkt491","volume":"69","author":"Olliaro P.","year":"2014","unstructured":"Olliaro P.; Delgado-Romero P.; Keiser J.; The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother 2014,69(4),863-870","journal-title":"J Antimicrob Chemother"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"701","DOI":"10.4155\/fmc.15.11","volume":"7","author":"Cupit P.M.","year":"2015","unstructured":"Cupit P.M.; Cunningham C.; What is the mechanism of action of praziquantel and how might resistance strike? Future Med Chem 2015,7(6),701-705","journal-title":"Future Med Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4172\/2157-7579.1000200","volume":"5","author":"Alsaqabi S.M.","year":"2014","unstructured":"Alsaqabi S.M.; Lotfy W.M.; Praziquantel: a review. J Veterinar Sci Technolo 2014,5,5","journal-title":"J Veterinar Sci Technolo"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","volume":"111","author":"Wang W.","year":"2012","unstructured":"Wang W.; Wang L.; Liang Y.S.; Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 2012,111(5),1871-1877","journal-title":"Parasitol Res"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051721","volume":"7","author":"Wu Z.H.","year":"2012","unstructured":"Wu Z.H.; Lu M.K.; Hu L.Y.; Li X.; Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One 2012,7(12)","journal-title":"PLoS One"},{"key":"ref=85","first-page":"231","author":"Willcox G.","year":"2005","unstructured":"Willcox G.; Bodeker G.; Rasoanaivo P.;  Traditional medicinal plants and Malaria 2005,231","journal-title":"Traditional medicinal plants and Malaria"},{"key":"ref=86","first-page":"835","author":"Goldsmith R.","year":"1989","unstructured":"Goldsmith R.; Botero D.;  1989,835-840"},{"key":"ref=87","first-page":"131","author":"Danis M.","year":"1991","unstructured":"Danis M.;  Medicaments antipaludiques in: Paludism; Danis, M 1991,131-145","journal-title":"Medicaments antipaludiques in: Paludism; Danis, M"},{"key":"ref=88","first-page":"100","author":"Richard-Lenoble D.","year":"1991","unstructured":"Richard-Lenoble D.; Lagardere B.;  Le paludisme et l\u2019enfant in: Paludism; Danis, M 1991,100-108","journal-title":"Le paludisme et l\u2019enfant in: Paludism; Danis, M"},{"key":"ref=89","first-page":"759","volume":"64","author":"Suebsaeng L.","year":"1986","unstructured":"Suebsaeng L.; Wernsdorfer W.H.; Rooney W.; Sensitivity to quinine and mefloquine of plasmodium falciparum in Thailand. Bull World Health Organ 1986,64(5),759-765","journal-title":"Bull World Health Organ"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0169-4758(90)90215-P","volume":"6","author":"Meshnick S.R.","year":"1990","unstructured":"Meshnick S.R.; Chloroquine as intercalator: a hypothesis revived. Parasitol Today 1990,6(3),77-79","journal-title":"Parasitol Today"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1017\/S003118200004662X","volume":"71","author":"Laser H.","year":"1975","unstructured":"Laser H.; Kemp P.; Miller N.; Lander D.; Klein R.; Malaria, quinine and red cell lysis. Parasitology 1975,71(2),167-181","journal-title":"Parasitology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0306-3623(96)00149-8","volume":"28","author":"Frayha G.J.","year":"1997","unstructured":"Frayha G.J.; Smyth J.D.; Gobert J.G.; Savel J.; The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 1997,28(2),273-299","journal-title":"Gen Pharmacol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0020-7519(90)90198-V","volume":"20","author":"Cowman A.F.","year":"1990","unstructured":"Cowman A.F.; Foote S.J.; Chemotherapy and drug resistance in malaria. Int J Parasitol 1990,20(4),503-513","journal-title":"Int J Parasitol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molbiopara.2011.01.012","volume":"177","author":"Okombo J.","year":"2011","unstructured":"Okombo J.; Ohuma E.; Picot S.; Nzila A.; Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol Biochem Parasitol 2011,177(2),77-82","journal-title":"Mol Biochem Parasitol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.virusres.2018.07.018","volume":"255","author":"Malakar S.","year":"2018","unstructured":"Malakar S.; Sreelatha L.; Dechtawewat T.; Noisakran S.; Yenchitsomanus P.T.; Chu J.J.H.; Limjindaporn T.; Drug repurposing of quinine as antiviral against dengue virus infection. Virus Res 2018,255,171-178","journal-title":"Virus Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1477-3163-2-9","volume":"2","author":"Grandics P.","year":"2003","unstructured":"Grandics P.; Cancer: a single disease with a multitude of manifestions? J Carcinog 2003,2(1),9","journal-title":"J Carcinog"},{"key":"ref=97","author":"Basco L.K.","year":"1994","unstructured":"Basco L.K.; Ruggeri C.; Le Bras J.;  Mol\u00e9cules antipalu-diques: m\u00e9canismes d\u2019action, m\u00e9canismes de r\u00e9sistance et relations strucutre-activit\u00e9 des schizontocides sanguins 1994","journal-title":"Mol\u00e9cules antipalu-diques: m\u00e9canismes d\u2019action, m\u00e9canismes de r\u00e9sistance et relations strucutre-activit\u00e9 des schizontocides sanguins"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.imlet.2013.07.004","volume":"153","author":"Thom\u00e9 R.","year":"2013","unstructured":"Thom\u00e9 R.; Lopes S.C.; Costa F.T.; Verinaud L.; Chloroquine: modes of action of an undervalued drug. Immunol Lett 2013,153(1-2),50-57","journal-title":"Immunol Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1046\/j.1365-3156.2001.00819.x","volume":"6","author":"D\u2019Alessandro U.","year":"2001","unstructured":"D\u2019Alessandro U.; Butti\u00ebns H.; History and importance of antimalarial drug resistance. Trop Med Int Health 2001,6(11),845-848","journal-title":"Trop Med Int Health"},{"key":"ref=100","first-page":"1","author":"Savel J.","year":"1993","unstructured":"Savel J.; Le Bras J.;  Antiparasitaires in: Encyclopedie Medico-Chirugicale Maladies Infectueuses 1993,1-19","journal-title":"Antiparasitaires in: Encyclopedie Medico-Chirugicale Maladies Infectueuses"},{"key":"ref=101","first-page":"695","author":"Remy-Kristensen A.","year":"1993","unstructured":"Remy-Kristensen A.; Pesson B.;  Mecanismes d\u2019action des antiparasitaires in: Pharmacologie Moleculaire Mecanisme d\u2019Action des Mediateurs et des Medicaments 1993,695-725","journal-title":"Mecanismes d\u2019action des antiparasitaires in: Pharmacologie Moleculaire Mecanisme d\u2019Action des Mediateurs et des Medicaments"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1128\/aac.32.6.799","volume":"32","author":"(a) Krogstad D. J.","year":"1988","unstructured":"(a) Krogstad D. J.; Schlesinger P. H.; Herwaldt B. L.;  Antimalarial agents: mechanism of chloroquine resistance Antimicrob Agents Chemother 1988,32(6),799-801","journal-title":"Antimalarial agents: mechanism of chloroquine resistance Antimicrob Agents Chemother"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2017.09.034","volume":"24","author":"Li C.","year":"2017","unstructured":"Li C.; Zhu X.; Ji X.; Quanquin N.; Deng Y.Q.; Tian M.; Aliyari R.; Zuo X.; Yuan L.; Afridi S.K.; Li X.F.; Jung J.U.; Nielsen-Saines K.; Qin F.X.; Qin C.F.; Xu Z.; Cheng G.; Chloroquine, a FDA-approved drug, prevents zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 2017,24,189-194","journal-title":"EBioMedicine"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.celrep.2016.12.051","volume":"18","author":"Burikhanov R.","year":"2017","unstructured":"Burikhanov R.; Hebbar N.; Noothi S.K.; Shukla N.; Sledziona J.; Araujo N.; Kudrimoti M.; Wang Q.J.; Watt D.S.; Welch D.R.; Maranchie J.; Harada A.; Rangnekar V.M.; Chloroquine-inducible par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis. Cell Rep 2017,18(2),508-519","journal-title":"Cell Rep"},{"key":"ref=105","unstructured":"Guidelines for the Treatment of malaria Pharmacology of antimalarial drugs: amodiaquine World Health Organization,( 3rd Edition), 2015 Available at:","journal-title":"Guidelines for the Treatment of malaria Pharmacology of antimalarial drugs: amodiaquine World Health Organization,( 3rd Edition), 2015 Available at:"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2217\/14622416.9.10.1385","volume":"9","author":"Gil J.P.","year":"2008","unstructured":"Gil J.P.; Amodiaquine pharmacogenetics. Pharmacogenomics 2008,9(10),1385-1390","journal-title":"Pharmacogenomics"},{"key":"ref=107","unstructured":"World Malaria Report World Health Organization 2016 Available at (Accessed Date: 11th September, 2017)","journal-title":"World Malaria Report World Health Organization 2016 Available at"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0035-9203(87)90311-7","volume":"81","author":"Khaliq A.A.","year":"1987","unstructured":"Khaliq A.A.; Fox E.; Sarwar M.; Strickland G.T.; Amodiaquine fails to cure chloroquine resistant Plasmodium falciparum in the Punjab. Trans R Soc Trop Med Hyg 1987,81(1),157-159","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/infdis\/158.6.1368","volume":"158","author":"Kremsner P.G.","year":"1988","unstructured":"Kremsner P.G.; Zotter G.M.; Feldmeier H.; Graninger W.; Rocha R.M.; Wiedermann G.; A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis 1988,158(6),1368-1371","journal-title":"J Infect Dis"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(05)66417-3","volume":"365","author":"Mutabingwa T.K.","year":"2005","unstructured":"Mutabingwa T.K.; Anthony D.; Heller A.; Hallett R.; Ahmed J.; Drakeley C.; Greenwood B.M.; Whitty C.J.; Amodiaquine alone, amodiaquine+sulfadoxine-pyrime-thamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005,365(9469),1474-1480","journal-title":"Lancet"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1038\/s41598-017-11924-4","volume":"7","author":"Salentin S.","year":"2017","unstructured":"Salentin S.; Adasme M.F.; Heinrich J.C.; Haupt V.J.; Daminelli S.; Zhang Y.; Schroeder M.; From malaria to cancer: computational drug repositioning of amodiaquine using PLIP interaction patterns. Sci Rep 2017,7(1),11401","journal-title":"Sci Rep"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202436","volume":"13","author":"McAnally D.","year":"2018","unstructured":"McAnally D.; Siddiquee K.; Gomaa A.; Szabo A.; Vasile S.; Maloney P.R.; Divlianska D.B.; Peddibhotla S.; Morfa C.J.; Hershberger P.; Falter R.; Williamson R.; Terry D.B.; Farjo R.; Pinkerton A.B.; Qi X.; Quigley J.; Boulton M.E.; Grant M.B.; Smith L.H.; Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS One 2018,13(9)","journal-title":"PLoS One"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/cns.12536","volume":"22","author":"Dong J.","year":"2016","unstructured":"Dong J.; Li S.; Mo J.L.; Cai H.B.; Le W.D.; Nurr1-based therapies for Parkinson\u2019s disease. CNS Neurosci Ther 2016,22(5),351-359","journal-title":"CNS Neurosci Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1073\/pnas.1509742112","volume":"112","author":"Kim C.H.","year":"2015","unstructured":"Kim C.H.; Han B.S.; Moon J.; Kim D.J.; Shin J.; Rajan S.; Nguyen Q.T.; Sohn M.; Kim W.G.; Han M.; Jeong I.; Kim K.S.; Lee E.H.; Tu Y.; Naffin-Olivos J.L.; Park C.H.; Ringe D.; Yoon H.S.; Petsko G.A.; Kim K.S.; Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson\u2019s disease. Proc Natl Acad Sci USA 2015,112(28),8756-8761","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2307\/3281795","volume":"72","author":"Campbell W.C.","year":"1986","unstructured":"Campbell W.C.; The chemotherapy of parasitic infections. J Parasitol 1986,72(1),45-61","journal-title":"J Parasitol"},{"key":"ref=116","unstructured":"Lariam summary of products characteristics. Availabe at: (Accessed Date: 1st September, 2017)"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1128\/AAC.21.4.581","volume":"21","author":"Chevli R.","year":"1982","unstructured":"Chevli R.; Fitch C.D.; The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob Agents Chemother 1982,21(4),581-586","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0169-4758(95)80201-0","volume":"11","author":"Mockenhaupt F.P.","year":"1995","unstructured":"Mockenhaupt F.P.; Mefloquine resistance in Plasmodium falciparum. Parasitol Today 1995,11(7),248-253","journal-title":"Parasitol Today"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/0140-6736(93)92409-M","volume":"341","author":"ter Kuile F.O.","year":"1993","unstructured":"ter Kuile F.O.; Dolan G.; Nosten F.; Edstein M.D.; Luxemburger C.; Phaipun L.; Chongsuphajaisiddhi T.; Webster H.K.; White N.J.; Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993,341(8852),1044-1049","journal-title":"Lancet"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"Price R.N.","year":"2004","unstructured":"Price R.N.; Uhlemann A.C.; Brockman A.; McGready R.; Ashley E.; Phaipun L.; Patel R.; Laing K.; Looareesuwan S.; White N.J.; Nosten F.; Krishna S.; Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004,364(9432),438-447","journal-title":"Lancet"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002975","volume":"8","author":"Keiser J.","year":"2014","unstructured":"Keiser J.; Silu\u00e9 K.D.; Adiossan L.K.; N\u2019Guessan N.A.; Monsan N.; Utzinger J.; N\u2019Goran E.K.; Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-prazi-quantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl Trop Dis 2014,8(7)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cas.13540","volume":"109","author":"Xu X.","year":"2018","unstructured":"Xu X.; Wang J.; Han K.; Li S.; Xu F.; Yang Y.; Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells. Cancer Sci 2018,109(4),1220-1229","journal-title":"Cancer Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbamem.2010.08.009","volume":"1808","author":"Basso L.G.","year":"2011","unstructured":"Basso L.G.; Rodrigues R.Z.; Naal R.M.; Costa-Filho A.J.; Effects of the antimalarial drug primaquine on the dynamic structure of lipid model membranes. Biochim Biophys Acta 2011,1808(1),55-64","journal-title":"Biochim Biophys Acta"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/2224-3151.213793","volume":"6","author":"Kitchakarn S.","year":"2017","unstructured":"Kitchakarn S.; Lek D.; Thol S.; Hok C.; Saejeng A.; Huy R.; Chinanonwait N.; Thimasarn K.; Wongsrichanalai C.; Implementation of G6PD testing and primaquine for P. vivax radical cure: operational perspectives from Thailand and Cambodia. WHO South-East Asia J Public Health 2017,6(2),60-68","journal-title":"WHO South-East Asia J Public Health"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jac\/dkv018","volume":"70","author":"Al-Bari M.A.","year":"2015","unstructured":"Al-Bari M.A.; Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 2015,70(6),1608-1621","journal-title":"J Antimicrob Chemother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1743-422X-10-177","volume":"10","author":"Barrow E.","year":"2013","unstructured":"Barrow E.; Nicola A.V.; Liu J.; Multiscale perspectives of virus entry via endocytosis. Virol J 2013,10,177","journal-title":"Virol J"},{"key":"ref=127","first-page":"1641","volume":"36","author":"Choi A.R.","year":"2016","unstructured":"Choi A.R.; Kim J.H.; Woo Y.H.; Kim H.S.; Yoon S.; Anti-malarial drugs primaquine and chloroquine have different sensitization effects with anti-mitotic drugs in resistant cancer cells. Anticancer Res 2016,36(4),1641-1648","journal-title":"Anticancer Res"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0031182000074746","volume":"106","author":"Davies C.S.","year":"1993","unstructured":"Davies C.S.; Pudney M.; Nicholas J.C.; Sinden R.E.; The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro. Parasitology 1993,106(Pt 1),1-6","journal-title":"Parasitology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"Wormser G.P.","year":"2006","unstructured":"Wormser G.P.; Dattwyler R.J.; Shapiro E.D.; Halperin J.J.; Steere A.C.; Klempner M.S.; Krause P.J.; Bakken J.S.; Strle F.; Stanek G.; Bockenstedt L.; Fish D.; Dumler J.S.; Nadelman R.B.; The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis 2006,43(9),1089-1134","journal-title":"Clin Infect Dis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/0006-2952(90)90256-K","volume":"39","author":"Dubin M.","year":"1990","unstructured":"Dubin M.; Fernandez Villamil S.H.; Stoppani A.O.M.; Inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions by beta-lapachone and related naphthoquinones. Biochem Pharmacol 1990,39(7),1151-1160","journal-title":"Biochem Pharmacol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1054\/drup.2000.0157","volume":"3","author":"Vaidya A.B.","year":"2000","unstructured":"Vaidya A.B.; Mather M.W.; Atovaquone resistance in malaria parasites. Drug Resist Updat 2000,3(5),283-287","journal-title":"Drug Resist Updat"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.tmaid.2017.12.005","volume":"21","author":"Savelkoel J.","year":"2018","unstructured":"Savelkoel J.; Binnendijk K.H.; Spijker R.; van Vugt M.; Tan K.; H\u00e4nscheid T.; Schlagenhauf P.; Grobusch M.P.; Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: a systematic review. Travel Med Infect Dis 2018,21,3-20","journal-title":"Travel Med Infect Dis"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/clinids\/24.3.422","volume":"24","author":"Torres R.A.","year":"1997","unstructured":"Torres R.A.; Weinberg W.; Stansell J.; Leoung G.; Kovacs J.; Rogers M.; Scott J.; Atovaquone\/toxoplasmic encephalitis study group. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1997,24(3),422-429","journal-title":"Clin Infect Dis"},{"key":"ref=134","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the prevention and treatment of opportunistic infections in HIV infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America  Available at: (Accessed Date: 5th November, 2017).","journal-title":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the prevention and treatment of opportunistic infections in HIV infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America  Available at:"},{"key":"ref=135","unstructured":"Summary of product characteristics of Malarone. Available at: (Accessed Date: 29th September, 2017)"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"34084","DOI":"10.18632\/oncotarget.9122","volume":"7","author":"Fiorillo M.","year":"2016","unstructured":"Fiorillo M.; Lamb R.; Tanowitz H.B.; Mutti L.; Krstic-Demonacos M.; Cappello A.R.; Martinez-Outschoorn U.E.; Sotgia F.; Lisanti M.P.; Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget 2016,7(23),34084-34099","journal-title":"Oncotarget"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/pharmaceutics10020060","volume":"10","author":"Takabe H.","year":"2018","unstructured":"Takabe H.; Warnken Z.N.; Zhang Y.; Davis D.A.; Smyth H.D.C.; Kuhn J.G.; Weitman S.; Williams Iii R.O.; A repurposed drug for brain cancer: enhanced atovaquone amorphous solid dispersion by combining a spontaneously emulsifying component with a polymer carrier. Pharmaceutics 2018,10(2),60","journal-title":"Pharmaceutics"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10863-018-9755-y","volume":"50","author":"Lv Z.","year":"2018","unstructured":"Lv Z.; Yan X.; Lu L.; Su C.; He Y.; Atovaquone enhances doxorubicin\u2019s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer. J Bioenerg Biomembr 2018,50(4),263-270","journal-title":"J Bioenerg Biomembr"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/CMR.5.4.387","volume":"5","author":"Speer B.S.","year":"1992","unstructured":"Speer B.S.; Shoemaker N.B.; Salyers A.A.; Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992,5(4),387-399","journal-title":"Clin Microbiol Rev"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0166-6851(88)90031-X","volume":"27","author":"Prapunwattana P.","year":"1988","unstructured":"Prapunwattana P.; O\u2019Sullivan W.J.; Yuthavong Y.; Depression of Plasmodium falciparum dihydroorotate dehydrogenase activity in in vitro culture by tetracycline. Mol Biochem Parasitol 1988,27(2-3),119-124","journal-title":"Mol Biochem Parasitol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s12936-015-0980-0","volume":"14","author":"Gaillard T.","year":"2015","unstructured":"Gaillard T.; Madamet M.; Pradines B.; Tetracyclines in malaria. Malar J 2015,14,445","journal-title":"Malar J"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12936-017-1797-9","volume":"16","author":"Gaillard T.","year":"2017","unstructured":"Gaillard T.; Briolant S.; Madamet M.; Pradines B.; The end of a dogma: the safety of doxycycline use in young children for malaria treatment. Malar J 2017,16(1),148-152","journal-title":"Malar J"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jinf.2016.02.001","volume":"72","author":"Lalloo D.G.","year":"2016","unstructured":"Lalloo D.G.; Shingadia D.; Bell D.J.; Beeching N.J.; Whitty C.J.M.; Chiodini P.L.; PHE advisory committee on malaria prevention in UK travellers. UK malaria treatment guidelines 2016. J Infect 2016,72(6),635-649","journal-title":"J Infect"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0049475515624857","volume":"46","author":"Gupta H.","year":"2016","unstructured":"Gupta H.; Dhunputh P.; Bhatt A.N.; Satyamoorthy K.; Umakanth S.; Cerebral malaria in a man with Plasmodium vivax mono-infection: a case report. Trop Doct 2016,46(4),241-245","journal-title":"Trop Doct"},{"key":"ref=145","author":"Rainey P.M.","year":"1989","unstructured":"Rainey P.M.; Santi D.V.;  Drugs for the treatment of leishmaniasis 1989","journal-title":"Drugs for the treatment of leishmaniasis"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00034983.1982.11687502","volume":"76","author":"Croft S.L.","year":"1982","unstructured":"Croft S.L.; Brazil R.P.; Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann Trop Med Parasitol 1982,76(1),37-43","journal-title":"Ann Trop Med Parasitol"},{"key":"ref=147","unstructured":"Summary of product characteristics for doxycycline. Available at:  smpc (Accessed Date: 13th September, 2017)"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"41755","DOI":"10.1038\/srep41755","volume":"7","author":"Gonz\u00e1lez-Liz\u00e1rraga F.","year":"2017","unstructured":"Gonz\u00e1lez-Liz\u00e1rraga F.; Soc\u00edas S.B.; \u00c1vila C.L.; Torres-Bugeau C.M.; Barbosa L.R.; Binolfi A.; Sep\u00falveda-D\u00edaz J.E.; Del-Bel E.; Fernandez C.O.; Papy-Garcia D.; Itri R.; Raisman-Vozari R.; Cheh\u00edn R.N.; Repurposing doxycycline for synucleinopathies: remodelling of \u03b1-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Sci Rep 2017,7(7),41755","journal-title":"Sci Rep"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/15384101.2016.1241929","volume":"16","author":"Zhang L.","year":"2017","unstructured":"Zhang L.; Xu L.; Zhang F.; Vlashi E.; Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle 2017,16(8),737-745","journal-title":"Cell Cycle"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actatropica.2014.02.012","volume":"134","author":"D\u00edaz M.V.","year":"2014","unstructured":"D\u00edaz M.V.; Miranda M.R.; Campos-Estrada C.; Reigada C.; Maya J.D.; Pereira C.A.; L\u00f3pez-Mu\u00f1oz R.; Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruzi. Acta Trop 2014,134,1-9","journal-title":"Acta Trop"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"11798","DOI":"10.1074\/jbc.M309341200","volume":"279","author":"Mehta A.","year":"2004","unstructured":"Mehta A.; Shaha C.; Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: complex II inhibition results in increased pentamidine cytotoxicity. J Biol Chem 2004,279(12),11798-11813","journal-title":"J Biol Chem"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","volume":"29","author":"Baker N.","year":"2013","unstructured":"Baker N.; de Koning H.P.; M\u00e4ser P.; Horn D.; Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol 2013,29(3),110-118","journal-title":"Trends Parasitol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1535-7163.MCT-13-0750","volume":"13","author":"Zerbini L.F.","year":"2014","unstructured":"Zerbini L.F.; Bhasin M.K.; de Vasconcellos J.F.; Paccez J.D.; Gu X.; Kung A.L.; Libermann T.A.; Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther 2014,13(7),1929-1941","journal-title":"Mol Cancer Ther"},{"key":"ref=154","first-page":"95","volume":"313","author":"Meshnick S.R.","year":"1989","unstructured":"Meshnick S.R.; Tsang T.W.; Lin F.B.; Pan H.Z.; Chang C.N.; Kuypers F.; Chiu D.; Lubin B.; Activated oxygen mediates the antimalarial activity of qinghaosu. Prog Clin Biol Res 1989,313,95-104","journal-title":"Prog Clin Biol Res"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/bs.armc.2018.08.003","volume":"51","author":"Franco J.","year":"2018","unstructured":"Franco J.; Scarone L.; Comini M.A.; Drugs and drug resistance in African and American Trypanosomiasis. Annual reports in medicinal chemistry. Annu Rep Med Chem 2018,51,97-133","journal-title":"Annu Rep Med Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.antiviral.2017.04.016","volume":"143","author":"Albulescu I.C.","year":"2017","unstructured":"Albulescu I.C.; Kovacikova K.; Tas A.; Snijder E.J.; van Hemert M.J.; Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res 2017,143,230-236","journal-title":"Antiviral Res"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.bbrc.2017.07.157","volume":"491","author":"Jeng-Wei L.","year":"2017","unstructured":"Jeng-Wei L.; Po-Shiuan H.; Chang-Chi L.; Ming-Kuan H.; Shih-Ming H.; Yu-Ming W.; Chun-Yu L.; Zhiyuan G.; Yi-Jung H.; Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem Biophys Res Commun 2017,491(3),595-602","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","volume":"19","author":"Croft S.L.","year":"2003","unstructured":"Croft S.L.; Coombs G.H.; Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003,19(11),502-508","journal-title":"Trends Parasitol"},{"key":"ref=159","first-page":"524","author":"Marr J.J.","year":"1991","unstructured":"Marr J.J.;  Purine metabolism in parasitic protozoa and its relationship to chemotherapy in: Biochemical Protozoology; Coombs, G 1991,524-536","journal-title":"Purine metabolism in parasitic protozoa and its relationship to chemotherapy in: Biochemical Protozoology; Coombs, G"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13071-015-0896-0","volume":"8","author":"Manna L.","year":"2015","unstructured":"Manna L.; Corso R.; Galiero G.; Cerrone A.; Muzj P.; Gravino A.E.; Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. Parasit Vectors 2015,8(8),289","journal-title":"Parasit Vectors"},{"key":"ref=161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005910","volume":"11","author":"Yasur-Landau D.","year":"2017","unstructured":"Yasur-Landau D.; Jaffe C.L.; Doron-Faigenboim A.; David L.; Baneth G.; Induction of allopurinol resistance in Leishmania infantum isolated from dogs. PLoS Negl Trop Dis 2017,11(9)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2174\/1568026616666160216152138","volume":"16","author":"Katare P.B.","year":"2016","unstructured":"Katare P.B.; Banerjee S.K.; Repositioning of drugs in cardiometabolic disorders: importance and current scenario. Curr Top Med Chem 2016,16(19),2189-2200","journal-title":"Curr Top Med Chem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1086\/511425","volume":"44","author":"Wendel K.A.","year":"2007","unstructured":"Wendel K.A.; Workowski K.A.; Trichomoniasis: challenges to appropriate management. Clin Infects Dis 2007,44,123-129","journal-title":"Clin Infects Dis"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0169-4758(93)90144-5","volume":"9","author":"Upcroft J.A.","year":"1993","unstructured":"Upcroft J.A.; Upcroft P.; Drug resistance and Giardia. Parasitol Today 1993,9(5),187-190","journal-title":"Parasitol Today"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1021\/ml200161t","volume":"3","author":"Kumar L.","year":"2011","unstructured":"Kumar L.; Jain A.; Lal N.; Sarswat A.; Jangir S.; Kumar L.; Singh V.; Shah P.; Jain S.; Maikhuri J.P.; Siddiqi M.I.; Gupta G.; Sharma V.L.; Potentiating metronidazole scaffold against resistant Trichomonas: design, synthesis, biology and 3D-QSAR analysis. ACS Med Chem Lett 2011,3(2),83-87","journal-title":"ACS Med Chem Lett"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"26051","DOI":"10.1074\/jbc.274.37.26051","volume":"274","author":"Wassmann C.","year":"1999","unstructured":"Wassmann C.; Hellberg A.; Tannich E.; Bruchhaus I.; Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 1999,274(37),26051-26056","journal-title":"J Biol Chem"},{"key":"ref=167","first-page":"100","volume":"25","author":"Gionchetti P.","year":"2012","unstructured":"Gionchetti P.; Calafiore A.; Riso D.; Liguori G.; Calabrese C.; Vitali G.; Laureti S.; Poggioli G.; Campieri M.; Rizzello F.; The role of antibiotics and probiotics in pouchitis. Ann Gastroenterol 2012,25(2),100-105","journal-title":"Ann Gastroenterol"},{"key":"ref=168","first-page":"13","volume":"24","author":"Bock M.","year":"1969","unstructured":"Bock M.; G\u00f6nnert R.; Haberkorn A.; Studies with Bay 2502 on animals. Bol Chil Parasitol 1969,24(1),13-19","journal-title":"Bol Chil Parasitol"},{"key":"ref=169","first-page":"282","volume":"101","author":"Richle R.","year":"1973","unstructured":"Richle R.; Chemotherapy of experimental acute Chagas disease in mice: beneficial effect of Ro-71051 on parasitemia and tissue parasitism. Prog Med (Paris) 1973,101,282","journal-title":"Prog Med (Paris)"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/s0074-02762002000100001","volume":"97","author":"Coura J.R.","year":"2002","unstructured":"Coura J.R.; Castro S.L.;  A critical review on chagas disease chemotherapy  Mem Inst Oswaldo Cruz, Rio de Janeiro 2002,97(1),3-24","journal-title":"A critical review on chagas disease chemotherapy  Mem Inst Oswaldo Cruz, Rio de Janeiro"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.molbiopara.2005.12.001","volume":"146","author":"Murta S.M.F.","year":"2006","unstructured":"Murta S.M.F.; Krieger M.A.; Montenegro L.R.; Campos F.F.M.; Probst C.M.; Avila A.R.; Muto N.H.; de Oliveira R.C.; Nunes L.R.; Nird\u00e9 P.; Bruna-Romero O.; Goldenberg S.; Romanha A.J.; Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol 2006,146(2),151-162","journal-title":"Mol Biochem Parasitol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1191\/0960327106het653oa","volume":"25","author":"Castro J.A.","year":"2006","unstructured":"Castro J.A.; de Mecca M.M.; Bartel L.C.; Toxic side effects of drugs used to treat Chagas\u2019 disease (American trypanosomiasis). Hum Exp Toxicol 2006,25(8),471-479","journal-title":"Hum Exp Toxicol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/cid\/ciw477","volume":"63","author":"Forsyth C.J.","year":"2016","unstructured":"Forsyth C.J.; Hernandez S.; Olmedo W.; Abuhamidah A.; Traina M.I.; Sanchez D.R.; Soverow J.; Meymandi S.K.; Safety profile of Nifurtimox for treatment of chagas disease in the United States. Clin Infect Dis 2016,63(8),1056-1062","journal-title":"Clin Infect Dis"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1128\/AAC.01401-12","volume":"57","author":"Pinazo M.J.","year":"2013","unstructured":"Pinazo M.J.; Guerrero L.; Posada E.; Rodr\u00edguez E.; Soy D.; Gascon J.; Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother 2013,57(1),390-395","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1073\/pnas.0711014105","volume":"105","author":"Wilkinson S.R.","year":"2008","unstructured":"Wilkinson S.R.; Taylor M.C.; Horn D.; Kelly J.M.; Cheeseman I.; A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008,105(13),5022-5027","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=176","first-page":"1084","volume":"7","author":"Li Q.","year":"2017","unstructured":"Li Q.; Lin Q.; Kim H.; Yun Z.; The anti-protozoan drug nifurtimox preferentially inhibits clonogenic tumor cells under hypoxic conditions. Am J Cancer Res 2017,7(5),1084-1095","journal-title":"Am J Cancer Res"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/173111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/173111\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/173111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T05:12:26Z","timestamp":1613797946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/173111\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":176,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2020,9,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190628163633","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}